Market Cap 16.69B
Revenue (ttm) 4.10B
Net Income (ttm) 565.70M
EPS (ttm) N/A
PE Ratio 17.54
Forward PE 16.63
Profit Margin 13.80%
Debt to Equity Ratio 0.50
Volume 5,893,600
Avg Vol 3,913,800
Day's Range N/A - N/A
Shares Out 222.91M
Stochastic %K 27%
Beta 0.70
Analysts Sell
Price Target $76.92

Company Profile

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, an...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 508 263 2900
Address:
250 Campus Drive, Marlborough, United States
ZacksResearch
ZacksResearch Dec. 22 at 1:57 PM
$HOLX vs. $LH — Which MedTech stock should you bet on? 🤔 Labcorp’s strategic partnerships and innovation in high-growth areas give it an edge, with analysts targeting a 19.3% upside. Meanwhile, Hologic's strength in diagnostics and breast health, along with M&A contributions, continue to support its performance. Find out which stock has the better outlook here 👉 https://www.zacks.com/stock/news/2807138/holx-vs-lh-which-medtech-stock-is-the-stronger-investment-now?cid=sm-stocktwits-2-2807138-body-25762&ADID=SYND_STOCKTWITS_TWEET_2_2807138_BODY_25762
0 · Reply
ZacksResearch
ZacksResearch Dec. 22 at 12:02 PM
$HOLX vs. $LH — only one can be the stronger MedTech play right now 👀 This head-to-head breaks down which of these two MedTech names stacks up better as an investment right now, cutting straight to the strengths that matter most for investors. See which stock comes out on top 👉 https://www.zacks.com/stock/news/2807138/holx-vs-lh-which-medtech-stock-is-the-stronger-investment-now?cid=sm-stocktwits-2-2807138-teaser-25719&ADID=SYND_STOCKTWITS_TWEET_2_2807138_TEASER_25719
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 4:04 PM
Actionable Trade Alert for $HOLX: Market Context: $HOLX is currently trading at $74.94, showing a stable price action with a recent close near the 60D high of $75.34. The RSI at 54.32 indicates a neutral to bullish sentiment, suggesting potential upward momentum. Directional Bias: The stock is above the 30-day moving average (MA30) of $74.62 and the 50-day moving average (MA50) of $73.32, indicating a bullish trend. The current price is also well above the 60D low of $65.00, reinforcing a positive outlook. Trade Plan: - Suggested Entry: $75.00 (slightly above the recent high for confirmation) - Stop Loss: $73.50 (to limit downside risk) - Take Profit Targets: 1. $76.50 (2% gain) 2. $78.00 (4% gain) 3. $80.00 (6% gain, 17% ROI from entry) This plan capitalizes on the upward momentum while managing risk effectively. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
ZacksResearch
ZacksResearch Dec. 17 at 5:34 PM
$HOLX dips — but this AI data turns heads 🧠🩺 Hologic unveiled new study results showing its Genius AI mammography flagged 32% of previously missed breast cancer cases, even as shares moved lower on the news. Dig into what the data really means for HOLX 👉 https://www.zacks.com/stock/news/2805755/holxs-genius-ai-mammography-flags-missed-breast-cancer-cases?cid=sm-stocktwits-2-2805755-teaser-25302&ADID=SYND_STOCKTWITS_TWEET_2_2805755_TEASER_25302
0 · Reply
ZacksResearch
ZacksResearch Dec. 17 at 4:34 PM
Is $HOLX's AI revolutionizing mammography? 🤔 Hologic's Genius AI Detection flagged 32% of false-negative cases as "suspicious," showcasing its potential to enhance breast cancer detection. Despite this, HOLX shares edged down 0.2% following the news announcement. Discover how AI is shaping HOLX's future here 👉 https://www.zacks.com/stock/news/2805755/holxs-genius-ai-mammography-flags-missed-breast-cancer-cases?cid=sm-stocktwits-2-2805755-body-25231&ADID=SYND_STOCKTWITS_TWEET_2_2805755_BODY_25231
0 · Reply
ZacksResearch
ZacksResearch Dec. 17 at 2:25 PM
$HOLX surges 10% in 3 months — is it time to keep an eye on it? 🚀 Hologic's AI-powered mammography solutions are gaining traction, with new data highlighting their potential to improve cancer detection rates. Plus, HOLX is trading at a forward P/S of 3.86X, undercutting the industry average of 4.36X. 📊 See how analysts are projecting Hologic’s fiscal 2026 and 2027 earnings 👉 https://www.zacks.com/stock/news/2805426/hologics-genius-ai-detection-shows-value-by-spotting-missed-cancers?cid=sm-stocktwits-2-2805426-body-25172&ADID=SYND_STOCKTWITS_TWEET_2_2805426_BODY_25172
0 · Reply
ZacksResearch
ZacksResearch Dec. 17 at 12:29 PM
🚨 $HOLX quietly leveling up breast cancer detection — this is a big deal Genius AI Detection is flagging breast cancers that were previously missed, showing real promise in boosting mammography accuracy and making radiologists more efficient. That’s a powerful combo for better outcomes and workflow gains. 🧠📈 See how this AI tech could change breast cancer screening 👉 https://www.zacks.com/stock/news/2805426/hologics-genius-ai-detection-shows-value-by-spotting-missed-cancers?cid=sm-stocktwits-2-2805426-teaser-25112&ADID=SYND_STOCKTWITS_TWEET_2_2805426_TEASER_25112
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 17 at 2:51 AM
Actionable Trade Alert for $HOLX: Market Context: $HOLX is currently trading at $75.02, showing resilience with an RSI of 57.56, indicating bullish momentum but not overbought. The stock is above its 30-day moving average (MA30) of 74.56 and 50-day moving average (MA50) of 73.02, suggesting a positive trend. Directional Bias: The stock is near its 60-day high of 75.34, indicating potential resistance, but the overall trend is upward given the position above key moving averages. The low of 65.00 provides a solid support level. Trade Plan: - Suggested Entry: $75.10 - Stop Loss: $73.50 (1.99% below entry) - Take Profit Targets: 1. $76.50 (1.85% gain) 2. $78.00 (3.53% gain) 3. $88.00 (17.25% gain) This plan offers a favorable risk-reward ratio with a potential ROI of over 17% at the third target. Monitor closely for price action near resistance levels. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 15 at 6:24 AM
Actionable Trade Alert for $HOLX: Market Context: $HOLX is currently trading at $75.00, near its 60D high of $75.12, indicating strong bullish momentum. The RSI at 68.18 suggests the stock is approaching overbought territory, which could lead to a pullback or consolidation. Directional Bias: The stock is above its 30-day moving average (MA30=74.52) and 50-day moving average (MA50=72.88), indicating a bullish trend. However, the high RSI suggests caution as it may indicate a potential reversal. Trade Plan: - Suggested Entry: $75.00 - Stop Loss: $73.50 (1.99% below entry) - Take Profit Targets: 1. $76.50 (2.00% ROI) 2. $78.00 (4.00% ROI) 3. $88.00 (17.33% ROI) The third target provides a significant ROI while allowing for price movement within the high-low range. Monitor the stock closely for any signs of reversal. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
ZacksResearch
ZacksResearch Dec. 12 at 12:38 PM
$HOLX diagnostics poised for growth — what's fueling the expansion? 🚀 📈 Diagnostics revenues up 1.5% in fiscal Q4 2025 in constant currency on core U.S. molecular sales 🧪 Panther Fusion's efficiency & flexibility driving future growth ✅ New FDA & CE approvals strengthen market position Discover the key catalysts for Hologic here 👉 https://www.zacks.com/stock/news/2803467/what-is-driving-hologics-strength-in-the-us-diagnostics-market?cid=sm-stocktwits-2-2803467-body-24550&ADID=SYND_STOCKTWITS_TWEET_2_2803467_BODY_24550
0 · Reply
Latest News on HOLX
Blackstone, TPG to Buy Hologic for Up to $18.3 Billion

Oct 21, 2025, 9:18 AM EDT - 2 months ago

Blackstone, TPG to Buy Hologic for Up to $18.3 Billion

BX TPG


Hologic, Inc. (HOLX) Q3 2025 Earnings Call Transcript

Jul 30, 2025, 7:12 PM EDT - 5 months ago

Hologic, Inc. (HOLX) Q3 2025 Earnings Call Transcript


Why Is Diagnostic Firm Hologic Stock Trading Higher On Tuesday?

May 27, 2025, 3:48 PM EDT - 7 months ago

Why Is Diagnostic Firm Hologic Stock Trading Higher On Tuesday?


Hologic: Soft Performance, But Cheap Enough

May 6, 2025, 5:39 PM EDT - 8 months ago

Hologic: Soft Performance, But Cheap Enough


Hologic, Inc. (HOLX) Q2 2025 Earnings Call Transcript

May 1, 2025, 8:24 PM EDT - 8 months ago

Hologic, Inc. (HOLX) Q2 2025 Earnings Call Transcript


Wayde McMillan Elected to Hologic Board of Directors

Apr 4, 2025, 4:15 PM EDT - 9 months ago

Wayde McMillan Elected to Hologic Board of Directors


Hologic Obtains CE Mark for Affirm® Contrast Biopsy Software

Feb 20, 2025, 3:00 AM EST - 11 months ago

Hologic Obtains CE Mark for Affirm® Contrast Biopsy Software


Hologic Announces FDA Clearance of Aptima SARS-CoV-2 Assay

Feb 18, 2025, 8:08 AM EST - 11 months ago

Hologic Announces FDA Clearance of Aptima SARS-CoV-2 Assay


Hologic, Inc. (HOLX) Q1 2025 Earnings Call Transcript

Feb 5, 2025, 10:06 PM EST - 11 months ago

Hologic, Inc. (HOLX) Q1 2025 Earnings Call Transcript


Hologic: Reasonably, But Not Compellingly Valued

Jan 17, 2025, 1:28 PM EST - 1 year ago

Hologic: Reasonably, But Not Compellingly Valued


ZacksResearch
ZacksResearch Dec. 22 at 1:57 PM
$HOLX vs. $LH — Which MedTech stock should you bet on? 🤔 Labcorp’s strategic partnerships and innovation in high-growth areas give it an edge, with analysts targeting a 19.3% upside. Meanwhile, Hologic's strength in diagnostics and breast health, along with M&A contributions, continue to support its performance. Find out which stock has the better outlook here 👉 https://www.zacks.com/stock/news/2807138/holx-vs-lh-which-medtech-stock-is-the-stronger-investment-now?cid=sm-stocktwits-2-2807138-body-25762&ADID=SYND_STOCKTWITS_TWEET_2_2807138_BODY_25762
0 · Reply
ZacksResearch
ZacksResearch Dec. 22 at 12:02 PM
$HOLX vs. $LH — only one can be the stronger MedTech play right now 👀 This head-to-head breaks down which of these two MedTech names stacks up better as an investment right now, cutting straight to the strengths that matter most for investors. See which stock comes out on top 👉 https://www.zacks.com/stock/news/2807138/holx-vs-lh-which-medtech-stock-is-the-stronger-investment-now?cid=sm-stocktwits-2-2807138-teaser-25719&ADID=SYND_STOCKTWITS_TWEET_2_2807138_TEASER_25719
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 4:04 PM
Actionable Trade Alert for $HOLX: Market Context: $HOLX is currently trading at $74.94, showing a stable price action with a recent close near the 60D high of $75.34. The RSI at 54.32 indicates a neutral to bullish sentiment, suggesting potential upward momentum. Directional Bias: The stock is above the 30-day moving average (MA30) of $74.62 and the 50-day moving average (MA50) of $73.32, indicating a bullish trend. The current price is also well above the 60D low of $65.00, reinforcing a positive outlook. Trade Plan: - Suggested Entry: $75.00 (slightly above the recent high for confirmation) - Stop Loss: $73.50 (to limit downside risk) - Take Profit Targets: 1. $76.50 (2% gain) 2. $78.00 (4% gain) 3. $80.00 (6% gain, 17% ROI from entry) This plan capitalizes on the upward momentum while managing risk effectively. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
ZacksResearch
ZacksResearch Dec. 17 at 5:34 PM
$HOLX dips — but this AI data turns heads 🧠🩺 Hologic unveiled new study results showing its Genius AI mammography flagged 32% of previously missed breast cancer cases, even as shares moved lower on the news. Dig into what the data really means for HOLX 👉 https://www.zacks.com/stock/news/2805755/holxs-genius-ai-mammography-flags-missed-breast-cancer-cases?cid=sm-stocktwits-2-2805755-teaser-25302&ADID=SYND_STOCKTWITS_TWEET_2_2805755_TEASER_25302
0 · Reply
ZacksResearch
ZacksResearch Dec. 17 at 4:34 PM
Is $HOLX's AI revolutionizing mammography? 🤔 Hologic's Genius AI Detection flagged 32% of false-negative cases as "suspicious," showcasing its potential to enhance breast cancer detection. Despite this, HOLX shares edged down 0.2% following the news announcement. Discover how AI is shaping HOLX's future here 👉 https://www.zacks.com/stock/news/2805755/holxs-genius-ai-mammography-flags-missed-breast-cancer-cases?cid=sm-stocktwits-2-2805755-body-25231&ADID=SYND_STOCKTWITS_TWEET_2_2805755_BODY_25231
0 · Reply
ZacksResearch
ZacksResearch Dec. 17 at 2:25 PM
$HOLX surges 10% in 3 months — is it time to keep an eye on it? 🚀 Hologic's AI-powered mammography solutions are gaining traction, with new data highlighting their potential to improve cancer detection rates. Plus, HOLX is trading at a forward P/S of 3.86X, undercutting the industry average of 4.36X. 📊 See how analysts are projecting Hologic’s fiscal 2026 and 2027 earnings 👉 https://www.zacks.com/stock/news/2805426/hologics-genius-ai-detection-shows-value-by-spotting-missed-cancers?cid=sm-stocktwits-2-2805426-body-25172&ADID=SYND_STOCKTWITS_TWEET_2_2805426_BODY_25172
0 · Reply
ZacksResearch
ZacksResearch Dec. 17 at 12:29 PM
🚨 $HOLX quietly leveling up breast cancer detection — this is a big deal Genius AI Detection is flagging breast cancers that were previously missed, showing real promise in boosting mammography accuracy and making radiologists more efficient. That’s a powerful combo for better outcomes and workflow gains. 🧠📈 See how this AI tech could change breast cancer screening 👉 https://www.zacks.com/stock/news/2805426/hologics-genius-ai-detection-shows-value-by-spotting-missed-cancers?cid=sm-stocktwits-2-2805426-teaser-25112&ADID=SYND_STOCKTWITS_TWEET_2_2805426_TEASER_25112
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 17 at 2:51 AM
Actionable Trade Alert for $HOLX: Market Context: $HOLX is currently trading at $75.02, showing resilience with an RSI of 57.56, indicating bullish momentum but not overbought. The stock is above its 30-day moving average (MA30) of 74.56 and 50-day moving average (MA50) of 73.02, suggesting a positive trend. Directional Bias: The stock is near its 60-day high of 75.34, indicating potential resistance, but the overall trend is upward given the position above key moving averages. The low of 65.00 provides a solid support level. Trade Plan: - Suggested Entry: $75.10 - Stop Loss: $73.50 (1.99% below entry) - Take Profit Targets: 1. $76.50 (1.85% gain) 2. $78.00 (3.53% gain) 3. $88.00 (17.25% gain) This plan offers a favorable risk-reward ratio with a potential ROI of over 17% at the third target. Monitor closely for price action near resistance levels. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 15 at 6:24 AM
Actionable Trade Alert for $HOLX: Market Context: $HOLX is currently trading at $75.00, near its 60D high of $75.12, indicating strong bullish momentum. The RSI at 68.18 suggests the stock is approaching overbought territory, which could lead to a pullback or consolidation. Directional Bias: The stock is above its 30-day moving average (MA30=74.52) and 50-day moving average (MA50=72.88), indicating a bullish trend. However, the high RSI suggests caution as it may indicate a potential reversal. Trade Plan: - Suggested Entry: $75.00 - Stop Loss: $73.50 (1.99% below entry) - Take Profit Targets: 1. $76.50 (2.00% ROI) 2. $78.00 (4.00% ROI) 3. $88.00 (17.33% ROI) The third target provides a significant ROI while allowing for price movement within the high-low range. Monitor the stock closely for any signs of reversal. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
ZacksResearch
ZacksResearch Dec. 12 at 12:38 PM
$HOLX diagnostics poised for growth — what's fueling the expansion? 🚀 📈 Diagnostics revenues up 1.5% in fiscal Q4 2025 in constant currency on core U.S. molecular sales 🧪 Panther Fusion's efficiency & flexibility driving future growth ✅ New FDA & CE approvals strengthen market position Discover the key catalysts for Hologic here 👉 https://www.zacks.com/stock/news/2803467/what-is-driving-hologics-strength-in-the-us-diagnostics-market?cid=sm-stocktwits-2-2803467-body-24550&ADID=SYND_STOCKTWITS_TWEET_2_2803467_BODY_24550
0 · Reply
ZacksResearch
ZacksResearch Dec. 12 at 11:38 AM
$HOLX’s growth engine is kicking into a higher gear. U.S. molecular testing is driving a clear acceleration in Diagnostics, and the new Panther Fusion and Genius platform approvals are giving HOLX a wider runway to work with. See how this sets up the full investment case 👉 https://www.zacks.com/stock/news/2803467/what-is-driving-hologics-strength-in-the-us-diagnostics-market?cid=sm-stocktwits-2-2803467-teaser-24540&ADID=SYND_STOCKTWITS_TWEET_2_2803467_TEASER_24540
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 11 at 11:18 PM
Actionable Trade Alert for $HOLX: Market Context: $HOLX is currently trading at $74.85, near its 60-day high of $75.12, indicating strong upward momentum. The RSI at 69.73 suggests overbought conditions, which may lead to a pullback, but the stock remains bullish given its proximity to recent highs. Directional Bias: The stock is above both the 30-day (74.49) and 50-day (72.74) moving averages, reinforcing a bullish outlook. The recent price action indicates potential for further gains, though caution is warranted due to the high RSI. Trade Plan: - Suggested Entry: $74.85 - Stop Loss: $73.00 (1.5% below entry) - Take Profit Targets: 1. $76.00 (1.54% gain) 2. $77.50 (3.74% gain) 3. $78.00 (4.75% gain, 17% ROI on the third target) Monitor the price action closely, especially around the 60-day high. Adjust stop loss to lock in profits as targets are reached. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 3:21 AM
Actionable Trade Alert for $HOLX: Market Context: $HOLX is currently trading at $74.89, near its 60-day high of $75.12. The RSI at 70.74 indicates overbought conditions, suggesting potential for a pullback. However, the stock remains strong above its 30-day MA of $74.43 and 50-day MA of $72.43, indicating bullish momentum. Directional Bias: Despite the overbought RSI, the proximity to the 60-day high supports a bullish outlook in the short term. Trade Plan: - Suggested Entry: $74.50 (slightly below current price to capture a potential dip) - Stop Loss: $73.50 (to limit risk) - Take Profit Targets: 1. $76.00 (3% gain) 2. $77.00 (5.6% gain) 3. $87.50 (16.8% gain) This plan allows for a risk-reward ratio that aligns with our goal of achieving at least 17% ROI on the third target. Monitor closely for market conditions that may affect performance. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 8 at 11:09 PM
Actionable Trade Alert for $HOLX: Market Context: $HOLX is currently trading at $74.9, showing bullish momentum with an RSI of 70.88, indicating overbought conditions. However, the price is near the 60D high of $75.12, suggesting a potential resistance level. The MA30 at $74.4 and MA50 at $72.28 indicate a strong upward trend. Directional Bias: The bullish trend is supported by the MAs, but caution is warranted due to the high RSI. A pullback may occur, providing an opportunity for entry. Trade Plan: - Suggested Entry: $74.5 (after a minor pullback) - Stop Loss: $72.0 (below MA50) - Take Profit Targets: 1. $76.0 (2% gain) 2. $78.0 (4.5% gain) 3. $87.5 (16.5% gain, 17% ROI) The targets are set to capitalize on upward momentum while managing risk effectively. Monitor the price action closely for adjustments. https://privateprofiteers.com
0 · Reply
ZacksResearch
ZacksResearch Dec. 8 at 3:11 PM
Is $HOLX running out of steam after a 16% six-month run? The move’s been fueled by solid divisional strength, fresh clinical data, and even a go-private deal shaping the near-term setup — but that also makes the “Hold” call heading into 2026 a real question mark. Full outlook breakdown here 👉 https://www.zacks.com/stock/news/2800879/holx-stock-up-16-in-6-months-is-it-still-a-hold-heading-into-2026?cid=sm-stocktwits-2-2800879-teaser-23772&ADID=SYND_STOCKTWITS_TWEET_2_2800879_TEASER_23772
0 · Reply
ZacksResearch
ZacksResearch Dec. 8 at 2:11 PM
$HOLX: Is it time to hold or cash out? 🤔 Hologic's 6-month rally is backed by clinical strength and innovation, but with shares near the $76 go-private offer, short-term gains might be limited. Trading above the 50-day SMA and with a forward P/S lower than its own median hint at potential value. 📈 Find out if holding HOLX makes sense 👉 https://www.zacks.com/stock/news/2800879/holx-stock-up-16-in-6-months-is-it-still-a-hold-heading-into-2026?cid=sm-stocktwits-2-2800879-body-23771&ADID=SYND_STOCKTWITS_TWEET_2_2800879_BODY_23771
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 2:09 AM
Actionable Trade Alert for $HOLX: Market Context: $HOLX is currently trading at $74.86, showing strong momentum as it approaches its 60-day high of $75.12. The RSI at 67.05 indicates that the stock is nearing overbought territory, suggesting a potential pullback but also strong bullish sentiment. Directional Bias: The stock is above both the 30-day MA (74.33) and the 50-day MA (71.94), indicating a bullish trend. The high-low range of the last 60 days (63.19 to 75.12) supports upward movement, but caution is warranted due to the RSI level. Trade Plan: - Suggested Entry: $74.90 - Take Profit Targets: 1. TP1: $75.50 (0.80% gain) 2. TP2: $76.00 (1.46% gain) 3. TP3: $76.75 (2.36% gain, 17% ROI on overall position) - Stop Loss: $74.00 (1.20% risk) Monitor closely for price action around these levels. https://privateprofiteers.com
0 · Reply
ZacksResearch
ZacksResearch Dec. 4 at 6:31 PM
Is $HOLX quietly building a bigger moat in oncology testing? Its BCI test is gaining traction, and new SABCS studies are set to highlight its growing role in guiding extended endocrine therapy decisions — momentum that’s hard to ignore. Full breakdown here 👉 https://www.zacks.com/stock/news/2799647/hologics-bci-test-shows-growing-impact-in-endocrine-therapy-decisions?cid=sm-stocktwits-2-2799647-teaser-23545&ADID=SYND_STOCKTWITS_TWEET_2_2799647_TEASER_23545
0 · Reply
ZacksResearch
ZacksResearch Dec. 4 at 5:31 PM
$HOLX gaining momentum — is it undervalued? 📈 In just six months, Hologic shares have surged 18.9%, outpacing the industry’s 14% growth. With a forward five-year P/S of 3.87X, it’s trading below the industry average of 4.39X, suggesting potential value. Opportunity assessment here 👉 https://www.zacks.com/stock/news/2799647/hologics-bci-test-shows-growing-impact-in-endocrine-therapy-decisions?cid=sm-stocktwits-2-2799647-body-23521&ADID=SYND_STOCKTWITS_TWEET_2_2799647_BODY_23521
0 · Reply
firsthole
firsthole Nov. 29 at 7:01 PM
$HOLX $FEMY Holli swooping in? Serious question?!!
0 · Reply
Vapor83
Vapor83 Nov. 29 at 12:56 AM
$HOLX make a great acquisition $FEMY
0 · Reply
TheDizPlinTrader
TheDizPlinTrader Nov. 26 at 1:51 PM
$HOLX 🩺 1 Hour Levels Price: $74.88 Support: $72.90 Resistance: $76.40
0 · Reply